Literature DB >> 971951

Cell-mediated immunity to Vibrio cholerae with ribonucleic acid-protein fractions of V. cholerae L-form lysates.

S C Agarwal, T Sundararaj.   

Abstract

Different L-form lysate vaccines of Vibrio cholerae serotypes Ogawa and Inaba and their combination along with ethyl alcohol-precipitated ribonucleic acid (E-RNA) and phenol-extracted RNA (P-RNA) fractions of V. cholerae Ogawa lysates were tested for production of cell-mediated immunity. Both E-RNA and P-RNA fractions induced an increase in leukocyte migration inhibition, macrophage migration inhibition, and macrophage aggregation. They also induced delayed hypersensitivity in rabbits. More consistent results were obtained with the P-RNA fraction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971951      PMCID: PMC420891          DOI: 10.1128/iai.14.2.363-367.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  DELAYED HYPERSENSITIVITY IN VITRO. I. THE SPECIFICITY OF INHIBITION OF CELL MIGRATION BY ANTIGENS.

Authors:  J R DAVID; S AL-ASKARI; H S LAWRENCE; L THOMAS
Journal:  J Immunol       Date:  1964-08       Impact factor: 5.422

2.  A new method for the isolation of ribonucleic acids from mammalian tissues.

Authors:  K S KIRBY
Journal:  Biochem J       Date:  1956-11       Impact factor: 3.857

3.  Macrophage aggregation in vitro: a correlate of delayed hypersensitivity.

Authors:  S Lolekha; S Dray; S P Gotoff
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

4.  Protection against Toxoplasma gondii in mice immunized with Toxoplasma cell fractions, RNA and synthetic polyribonucleotides.

Authors:  F G Araujo; J S Remington
Journal:  Immunology       Date:  1974-10       Impact factor: 7.397

5.  The relationship of delayed hypersensitivity to acquired antituberculous immunity. II. Effect of adjuvant on the allergenicity and immunogenicity of heat-killed tubercle bacilli.

Authors:  F M Collins; G B Mackaness
Journal:  Cell Immunol       Date:  1970-09       Impact factor: 4.868

6.  Experimental oral immunization with L-forms of Vibrio cholerae.

Authors:  S C Agarwal; N K Ganguly
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

7.  Relationship between tuberculin hypersensitivity and cellular immunity to infection in mice vaccinated with viable attenuated Mycobacterial cells or with Mycobacterial ribonucleic acid preparations.

Authors:  R G Neiburger; G P Youmans; A S Youmans
Journal:  Infect Immun       Date:  1973-07       Impact factor: 3.441

8.  Oral immunization with L-forms of Vibrio cholerae in human volunteers.

Authors:  S C Agarwal; N K Ganguly
Journal:  Infect Immun       Date:  1972-07       Impact factor: 3.441

9.  Immunogenicity of Ribonucleic Acid Preparations Obtained from Salmonella typhimurium.

Authors:  M R Venneman; N J Bigley; L J Berry
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

10.  Cellular immunity in vitro. I. Immunologically mediated enhancement of macrophage bactericidal capacity.

Authors:  H B Simon; J N Sheagren
Journal:  J Exp Med       Date:  1971-06-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Pathophysiological effects of Vibrio cholerae and enterotoxigenic Escherichia coli and their exotoxins on eucaryotic cells.

Authors:  K L Richards; S D Douglas
Journal:  Microbiol Rev       Date:  1978-09

2.  Cell-mediated immunity after oral immunization with ribonucleic acid-protein fractions of Vibrio cholerae L-form lysates.

Authors:  S C Agarwal; T Sundararaj
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

3.  Cell-mediated immunity in experimental Nocardia asteroides infection.

Authors:  T Sundararaj; S C Agarwal
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

4.  Leucocyte migration inhibition with human heart valve glycoproteins and group A streptococcal ribonucleic acid proteins in rheumatic heart disease and post-streptococcal glomerulonephritis.

Authors:  R Gowrishankar; S C Agarwal
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.